Vaxcyte Inc
PCVX
Market Cap$7B
Close$
$3.79
94.1% downside
Current Fair Value
94.1% downsideOvervalued by 94.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.00 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 0.61 |
| Outstanding Shares | 108,407,730 |
| Avg 30 Day Volume | 696,856 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About Vaxcyte Inc
14,000 employees
CEO: Grant Pickering Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-fre...